EPHA1, EPH receptor A1, 2041

N. diseases: 119; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006287
Disease: Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia 		0.010 Biomarker disease BEFREE We identified novel factors and confirmed previously established factors with development of LPH and EPH, which can help develop a screening strategy in BPD patients. 31723236 2020
CUI: C0005779
Disease: Blood Coagulation Disorders
Blood Coagulation Disorders 		0.010 Biomarker group BEFREE Novel genes recently implicated in human platelet dysfunction include the galactose metabolism enzyme UDP-galactose-4-epimerase in macrothrombocytopenia, and erythropoietin-producing hepatoma-amplified sequence receptor transmembrane tyrosine kinase EPHB2 in a severe bleeding disorder with deficiencies in platelet agonist response and granule secretion. 31348050 2019
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.010 AlteredExpression phenotype BEFREE Eph receptor A3 (EphA3) expression is associated with tumor promotion in certain types of cancer; however, it acts as a tumor suppressor in others. 30483759 2019
CUI: C0025149
Disease: Medulloblastoma
Medulloblastoma 		0.010 Biomarker disease BEFREE We present here the involvement of Eph receptors and ephrin ligands in lung carcinoma, breast carcinoma, prostate carcinoma, colorectal carcinoma, glioblastoma, and medulloblastoma. 29682554 2018
CUI: C0025286
Disease: Meningioma
Meningioma 		0.010 Biomarker disease BEFREE Co-targeting mTORC1/2 and EPH RTK/SFK pathways could be a novel effective treatment strategy for NF2-deficient meningiomas. 29982664 2018
CUI: C0027832
Disease: Neurofibromatosis 2
Neurofibromatosis 2 		0.010 Biomarker disease BEFREE Co-targeting mTORC1/2 and EPH RTK/SFK pathways could be a novel effective treatment strategy for NF2-deficient meningiomas. 29982664 2018
CUI: C0206701
Disease: Cystadenocarcinoma, Serous
Cystadenocarcinoma, Serous 		0.010 Biomarker disease BEFREE EphA1 protein was detected in ovarian cancer cell lines and in a set of formalin‑fixed tissues, including normal fallopian tube, ovarian benign serous cystadenoma, borderline serous tumors and serous carcinoma. 29393455 2018
CUI: C0206709
Disease: Cystadenoma, Serous
Cystadenoma, Serous 		0.010 AlteredExpression disease BEFREE EphA1 expression was positively detected in all normal fallopian tubes (10/10, 100%) and ovarian benign serous cystadenomas (12/12, 100%) as well as in some borderline serous tumors (9/15, 60%) and ovarian serous carcinomas (33/76, 43.42%). 29393455 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.010 GeneticVariation disease BEFREE At the suggestive threshold (P < .001), 6 genes were enriched for rare damaging variants (UHMK1, AP1G2, DNTA, CHST6, FGFR3, and EPHA1) and 7 genes had associations with pancreatic cancer risk, based on the sequence-kernel association test. 29074453 2018
CUI: C0278510
Disease: Childhood Medulloblastoma
Childhood Medulloblastoma 		0.010 Biomarker disease BEFREE We present here the involvement of Eph receptors and ephrin ligands in lung carcinoma, breast carcinoma, prostate carcinoma, colorectal carcinoma, glioblastoma, and medulloblastoma. 29682554 2018
CUI: C0278876
Disease: Adult Medulloblastoma
Adult Medulloblastoma 		0.010 Biomarker disease BEFREE We present here the involvement of Eph receptors and ephrin ligands in lung carcinoma, breast carcinoma, prostate carcinoma, colorectal carcinoma, glioblastoma, and medulloblastoma. 29682554 2018
CUI: C0278877
Disease: Adult Meningioma
Adult Meningioma 		0.010 Biomarker disease BEFREE EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. 29982664 2018
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.010 GeneticVariation disease BEFREE At the suggestive threshold (P < .001), 6 genes were enriched for rare damaging variants (UHMK1, AP1G2, DNTA, CHST6, FGFR3, and EPHA1) and 7 genes had associations with pancreatic cancer risk, based on the sequence-kernel association test. 29074453 2018
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.010 AlteredExpression group BEFREE The Eph tyrosine kinase receptors expressed in neurons are important in many contexts during neural-circuit formation, such as axon outgrowth, axon guidance, and synaptic formation, and have been suggested to be involved in neurodegenerative disorders, including amyotrophic lateral sclerosis and Alzheimer's disease. 29363583 2018
CUI: C1335177
Disease: Ovarian Serous Adenocarcinoma
Ovarian Serous Adenocarcinoma 		0.010 Biomarker disease BEFREE These data suggest that EphA1 might be a useful marker for distinguishing low grade from high‑grade ovarian serous carcinoma. 29393455 2018
CUI: C1762616
Disease: Meningioma, benign, no ICD-O subtype
Meningioma, benign, no ICD-O subtype 		0.010 Biomarker disease BEFREE EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. 29982664 2018
CUI: C3266262
Disease: Multiple Chronic Conditions
Multiple Chronic Conditions 		0.010 Biomarker disease BEFREE The availability of high-resolution structures of the multi-modular Eph receptors in complexes with ephrins and other binding partners, such as peptides, small molecule inhibitors and antibodies, offers a wealth of information for the structure-guided development of therapeutic intervention. 30343150 2018
CUI: C0011644
Disease: Scleroderma
Scleroderma 		0.010 Biomarker disease BEFREE The prevalence of EPAH in scleroderma may be as high as 50%. 28284324 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.010 Biomarker disease BEFREE However, the importance of EphA1 in diabetic nephropathy has not been recognized. 28341121 2017
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma 		0.010 Biomarker disease BEFREE The prevalence of EPAH in scleroderma may be as high as 50%. 28284324 2017
CUI: C0086543
Disease: Cataract
Cataract 		0.010 Biomarker disease BEFREE Due to this complex expression pattern and the promiscuous interactions between Eph receptors and ephrin ligands, as well as their complex bidirectional signaling pathways, cataracts in ephrin-A5(-/-) or EphA2(-/-) lenses may arise from loss of function or abnormal signaling mechanisms. 28648759 2017
CUI: C0521707
Disease: Bilateral cataracts (disorder)
Bilateral cataracts (disorder) 		0.010 Biomarker disease BEFREE Due to this complex expression pattern and the promiscuous interactions between Eph receptors and ephrin ligands, as well as their complex bidirectional signaling pathways, cataracts in ephrin-A5(-/-) or EphA2(-/-) lenses may arise from loss of function or abnormal signaling mechanisms. 28648759 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.010 Biomarker disease BEFREE EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC. 28739735 2017
CUI: C3203102
Disease: Idiopathic pulmonary arterial hypertension
Idiopathic pulmonary arterial hypertension 		0.010 GeneticVariation disease BEFREE The underlying pathophysiology of the arterial form of EPH (EPAH) appears to be similar to that seen in resting pulmonary arterial hypertension (PAH), and EPAH individuals are at risk of developing resting PAH. 28284324 2017
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.010 Biomarker disease BEFREE EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC. 28739735 2017